Szerző szerinti böngészés "Shinjo, Samuel Katsuyuki"
Megjelenítve 1 - 7 (Összesen 7)
Találat egy oldalon
Rendezési lehetőségek
Tétel Szabadon hozzáférhető Autoantibodies and damage in patients with idiopathic inflammatory myopathies: A longitudinal multicenter study from the MYONET international networkEspinosa-Ortega, Fabricio; Lodin, Karin; Dastmalchi, Maryam; Vencovsky, Jiri; Diederichsen, Louise P; Shinjo, Samuel Katsuyuki; Danieli, Maria Giovanna; Selva-O'Callaghan, Albert; de Visser, Marianne; Griger, Zoltan; Ceribelli, Angela; Gómez-Martin, Diana; Andersson, Helena; Mercado, Mónica Vázquez-Del; Chinoy, Hector; Lilleker, James B; New, Paul; Krogh, Niels S; Lundberg, Ingrid E; Alexanderson, Helene; Griger Zoltán (1979-) (belgyógyász, allergológus és klinikai immunológus, reumatológus); Belgyógyászati Intézet -- 84; Klinikai Immunológiai Tanszék -- 60; ÁOK; Debreceni EgyetemObjective To study the trajectories of changes in damage over time and explore associations with autoantibody defined subgroups using a large international cohort of patients with idiopathic inflammatory myopathies (IIM). Methods Data from the MYONET registry, including patients who were tested for autoantibodies and had at least one assessment of damage using the Myositis Damage Index (MDI), were analyzed. Patients were sub-grouped according to their autoantibody profiles (myositis-specific, myositis-associated, or seronegative). The index date was defined as the time point for the first registered MDI assessment. The longitudinal trajectories of damage with autoantibody status as the main predictor were analyzed using linear mixed models. Results A total of 757 adult patients were included in this study. Each year of disease duration since diagnosis had an estimated MDI score increase of 0.16 units for the seronegative group (reference). Compared with the seronegative group as reference, patients with dermatomyositis-specific autoantibodies developed less damage per year of follow-up since diagnosis (average 0.08 less score, P = 0.04), whereas patients with anti-PM/Scl autoantibodies developed more damage per year of follow-up since diagnosis (average 0.28 higher score, P = 0.03) independent of sex and age at diagnosis. The seronegative subgroup and the immune-mediated necrotizing myopathy autoantibody subgroup had the strongest correlation between severity of muscle damage and HAQ-DI scores at five years of follow-up, rho=0.84, P < 0.001 and rho=0.72, P < 0.001, respectively. Conclusion Our study is the first to describe patterns and trajectories of change in damage over time in relation to autoantibody defined subgroups in a large international multicenter cohort of patients with IIM. Patients with anti-PM/Scl scored a greater extent of damage, whereas patients with dermatomyositis-specific antibodies had less damage than seronegative patients. Severity in muscle damage had moderate to strong correlation with functional disability among the IMNM and seronegative subgroups with lower correlations for the other subgroups. These findings suggest that autoantibodies may be useful predictors of long-term damage.Tétel Szabadon hozzáférhető Characteristics of emerging new autoimmune diseases after COVID‐19 vaccination: A sub‐study by the COVAD groupShumnalieva, Russka; Ravichandran, Naveen; Hannah, Jennifer; Javaid, Mahnoor; Darooka, Naitica; Roy, Debaditya; Gonzalez, Daniel E.; Velikova, Tsvetelina; Milchert, Marcin; Kuwana, Masataka; Joshi, Mrudula; Gracia‐Ramos, Abraham Edgar; Boyd, Peter; Yaadav, Praggya; Cheng, Karen; Kobert, Linda; Cavagna, Lorenzo; Sen, Parikshit; Day, Jessica; Makol, Ashima; Gutiérrez, Carlos Enrique Toro; Caballero‐Uribe, Carlo V.; Saha, Sreoshy; Parodis, Ioannis; Dey, Dzifa; Nikiphorou, Elena; Distler, Oliver; Kadam, Esha; Tan, Ai Lyn; Shinjo, Samuel Katsuyuki; Ziade, Nelly; Knitza, Johannes; Chinoy, Hector; Aggarwal, Rohit; Agarwal, Vikas; Gupta, Latika; Griger Zoltán (1979-) (belgyógyász, allergológus és klinikai immunológus, reumatológus); Belgyógyászati Intézet -- 84; Klinikai Immunológiai Tanszék -- 60; ÁOK; Debreceni EgyetemBackground Despite the overall safety and efficacy of COVID-19 vaccinations, rare cases of systemic autoimmune diseases (SAIDs) have been reported post-vaccination. This study used a global survey to analyze SAIDs in susceptible individuals' post-vaccination. Methods A cross-sectional study was conducted among participants with self-reported new-onset SAIDs using the COVID-19 Vaccination in Autoimmune Diseases (COVAD) 2 study dataset—a validated, patient-reported e-survey—to analyze the long-term safety of COVID-19 vaccines. Baseline characteristics of patients with new-onset SAIDs and vaccinated healthy controls (HCs) were compared after propensity score matching based on age and sex in a 1:4 ratio. Results Of 16 750 individuals, 74 (median age 52 years, 79.9% females, and 76.7% Caucasians) had new-onset SAID post-vaccination, mainly idiopathic inflammatory myopathies (IIMs) (n = 23, 31.51%), arthritis (n = 15; 20.53%), and polymyalgia rheumatica (PMR) (n = 12, 16.40%). Higher odds of new-onset SAIDs were noted among Caucasians (OR = 5.3; 95% CI = 2.9–9.7; p < .001) and Moderna vaccine recipients (OR = 2.7; 95% CI = 1.3–5.3; p = .004). New-onset SAIDs were associated with AID multimorbidity (OR = 1.4; 95% CI = 1.1–1.7; p < .001), mental health disorders (OR = 1.6; 95% CI = 1.3–1.9; p < .001), and mixed race (OR = 2.2; 95% CI = 1.2–4.2; p = .010), where those aged >60 years (OR = 0.6; 95% CI = 0.4–0.8; p = .007) and from high/medium human development index (HDI) countries (compared to very high HDI) reported fewer events than HCs. Conclusion This study reports a low occurrence of new-onset SAIDs following COVID-19 vaccination, primarily IIMs, PMR, and inflammatory arthritis. Identified risk factors included pre-existing AID multimorbidity, mental health diseases, and mixed race. Revaccination was well tolerated by most patients; therefore, we recommend continuing COVID-19 vaccination in the general population. However, long-term studies are needed to understand the autoimmune phenomena arising post-vaccination.Tétel Szabadon hozzáférhető COVAD survey 2 long-term outcomes: unmet need and protocol(2022) Fazal, Zoha Zahid; Sen, Parikshit; Joshi, Mrudula; Ravichandran, Naveen; Lilleker, James B.; Agarwal, Vishwesh; Kardes, Sinan; Kim, Minchul; Day, Jessica; Makol, Ashima; Milchert, Marcin; Gheita, Tamer A.; Salim, Babur; Velikova, Tsvetelina; Gracia-Ramos, Abraham Edgar; Parodis, Ioannis; Nikiphorou, Elena; Tan, Ai Lyn; Chatterjee, Tulika; Cavagna, Lorenzo; Saavedra, Miguel A.; Shinjo, Samuel Katsuyuki; Ziade, Nelly; Selva-O'Callaghan, Albert; Nune, Arvind; Knitza, Johannes; Kuwana, Masataka; Gutiérrez, Carlos-Enrique Toro; Caballero-Uribe, Carlo Vinicio; Dey, Dzifa; Distler, Oliver; Chinoy, Hector; Agarwal, Vikas; Aggarwal, Rohit; Gupta, Latika; Nagy-Vincze, Melinda; Griger, ZoltánTétel Szabadon hozzáférhető COVID-19 breakthrough infections in type 1 diabetes mellitus: a cross-sectional study by the COVID-19 Vaccination in Autoimmune Diseases (COVAD) Group(2023) Panchawagh, Suhrud; Ravichandran, Naveen; Barman, Bhupen; Nune, Arvind; Javaid, Mahnoor; Gracia-Ramos, Abraham Edgar; Day, Jessica; Joshi, Mrudula; Kuwana, Masataka; Saha, Sreoshy; Pande, Arunkumar R.; Caballero-Uribe, Carlo Vinicio; Velikova, Tsvetelina; Parodis, Ioannis; Knitza, Johannes; Kadam, Esha; Tan, Ai Lyn; Shinjo, Samuel Katsuyuki; Boro, Hiya; Aggarwal, Rohit; Agarwal, Vikas; Chatterjee, Tulika; Gupta, Latika; Griger, Zoltán; Nagy-Vincze, MelindaTétel Szabadon hozzáférhető Long-term safety of COVID vaccination in individuals with idiopathic inflammatory myopathies: results from the COVAD study(2023) Doskaliuk, Bohdana; Ravichandran, Naveen; Sen, Parikshit; Day, Jessica; Joshi, Mrudula; Nune, Arvind; Nikiphorou, Elena; Saha, Sreoshy; Tan, Ai Lyn; Shinjo, Samuel Katsuyuki; Ziade, Nelly; Velikova, Tsvetelina; Milchert, Marcin; Jagtap, Kshitij; Parodis, Ioannis; Gracia-Ramos, Abraham Edgar; Cavagna, Lorenzo; Kuwana, Masataka; Knitza, Johannes; Chen, Yi Ming; Makol, Ashima; Agarwal, Vishwesh; Patel, Aarat; Pauling, John D.; Wincup, Chris; Barman, Bhupen; Tehozol, Erick Adrian Zamora; Serrano, Jorge Rojas; La Torre, Ignacio García-De; Colunga-Pedraza, Iris J.; Merayo-Chalico, Javier; Chibuzo, Okwara Celestine; Katchamart, Wanruchada; Akawatcharangura Goo, Phonpen; Shumnalieva, Russka; Hoff, Leonardo Santos; Kibbi, Lina El; Halabi, Hussein; Vaidya, Binit; Shaharir, Syahrul Sazliyana; Hasan, A. T. M. Tanveer; Dey, Dzifa; Gutiérrez, Carlos-Enrique Toro; Caballero-Uribe, Carlo Vinicio; Lilleker, James B.; Salim, Babur; Gheita, Tamer A.; Chatterjee, Tulika; Distler, Oliver; Saavedra, Miguel A.; Chinoy, Hector; Agarwal, Vikas; Aggarwal, Rohit; Gupta, Latika; Griger, Zoltán; Nagy-Vincze, MelindaTétel Szabadon hozzáférhető Patient global assessment and inflammatory markers in patients with idiopathic inflammatory myopathies: a longitudinal study(2024) Lodin, Karin; Espinosa-Ortega, Fabricio; Dastmalchi, Maryam; Vencovsky, Jiri; Andersson, Helena; Chinoy, Hector; Lilleker, James B.; Shinjo, Samuel Katsuyuki; Maurer, Britta; Griger, Zoltán; Ceribelli, Angela; Torres-Ruiz, Jiram; Mercado, Mónica Vázquez-Del; Leonard, Dag; Alexanderson, Helene; Lundberg, IngridTétel Szabadon hozzáférhető Type 1 diabetes, COVID-19 vaccines and short-term safety: subgroup analysis from the global COVAD study(2024) Chatterjee, Tulika; Ravichandran, Naveen; Nair, Narmadha; Gracia-Ramos, Abraham Edgar; Barman, Bhupen; Sen, Parikshit; Joshi, Mrudula; Saha, Sreoshy; Nune, Arvind; Pande, Arunkumar R.; Velikova, Tsvetelina; Parodis, Ioannis; Tan, Ai Lyn; Shinjo, Samuel Katsuyuki; Boro, Hiya; Agarwal, Vikas; Aggarwal, Rohit; Gupta, Latika; Nagy-Vincze, Melinda